FI  Euclidean Capital




     Office Locations:

160 5th Ave #9
New York, NY 10010

 

Stages:

  • Expansion
  • Growth


 

Industries:

  • Business Services
  • Financial Services
  • Life Sciences & Healthcare
  • Software & Internet

  •  

    Description:

    Euclidean Capital, the family office for hedge fund billionaire James Simons. Simons is the founder of one of the world's most successful hedge funds, Renaissance Technologies, which has around $25 billion under management. Ashvin Chhabra, the former chief investment officer of Bank of America Corp's Merrill Lynch Wealth Management, helps to run the firm. Euclidean Capital had 20 active participants in its 401(k) plan as of 2013, according to its latest filing with the Department of Labor.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Ashvin Chhabra President
    Fred Tencic

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      02/22/2018


      Kallyope


      NY


      $66,000,000


      Series B


      01/29/2018


      Ripple Foods


      CA


      $65,000,000


      Series C


      09/12/2017


      23andMe


      CA


      $250,000,000


      Growth


     

    Portfolio companies include:


      23andMe
        web link


      Imagen Technologies
        web link


      Kallyope
        web link


      PMV Pharma
        web link


      Ripple Foods
        web link


     

    Recent News:


      There is no recent news for Euclidean Capital.